# SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC

Source: https://onco.cc/trials/nct07549399/  
OnCo record `nct07549399` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of cetuximab and bevacizumab (glioblastoma use) in colorectal cancer, run by Sixth Affiliated Hospital, Sun Yat-sen University, now recruiting.

## Summary

SCRT + Chemo Targeted Immuno-neoadjuvant Therapy for High-risk pMMR/MSS RC is a phase 3, randomised interventional study registered as NCT07549399 by Sixth Affiliated Hospital, Sun Yat-sen University, with a registry enrolment figure of 204 participants, started 2026-05-20 and due to reach its primary completion in 2029-04-30. Interventions recorded: Short-Course Radiotherapy; PD-1 monoclonal antibody; mFOLFOX6 regimen; Cetuximab; Bevacizumab; Surgical resection. Conditions listed: Rectal Adenocarcinoma; High-Risk Cancer; MSS. Primary outcome: 3 years DFS Rate. Colorectal eligibility wording from the registry: "Histologically or cytologically confirmed pMMR/MSS rectal adenocarcinoma; all other histological types are excluded". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: CRITII
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07549399
- Phase: 3
- Setting: Short-Course Radiotherapy Combined With mFOLFOX6, PD-1 Antibody and Cetuximab (for RAS/BRAF Wild-Type)/Bevacizumab (for RAS/BRAF Mutant) in High-Risk pMMR/MSS Rectal Adenocarcinoma: a Phase III Randomized Controlled Trial
- Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
- Enrolled: 204

## Sources

- ClinicalTrials.gov NCT07549399: https://clinicaltrials.gov/study/NCT07549399

## Connected records

- cancers: [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [IMRT / IGRT (modern external beam)](https://onco.cc/technologies/imrt-igrt/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab (glioblastoma use)](https://onco.cc/drugs/bevacizumab-glioma/), [Cetuximab](https://onco.cc/drugs/cetuximab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07549399.json